Reveal-Dx's core product, RevealAI-Lung, analyzes incidental lung nodules on CT scans and produces a Malignancy Similarity Index to inform radiologist follow-up recommendations. The company reports validating the software on more than 1,500 patients across varied cohorts. RevealAI-Lung has received CE marking under the EU Medical Device Regulation, approval from Australia's Therapeutic Goods Administration, and clearance from the U.S. Food and Drug Administration. The software is reimbursable by Medicare under CPT codes 0721T and 0722T. As part of a commercial expansion, Reveal-Dx has struck a distribution agreement with 4DMedical to extend distribution into the U.S., Europe, Australia and New Zealand. The company also received a $3.4 million strategic investment from 4DMedical as part of that agreement.

Total raised

$8M

Funding rounds

2

Latest round

Equity

Latest activity

Aug 2026